Overview


According to FutureWise analysis the market for diabetic nephropathy in 2023 is US$ 3.52 billion, and is expected to reach US$ 5.83 billion by 2031 at a CAGR of 6.5%.

Diabetic nephropathy is characterized by the development of hypertension and hyperglycaemia, resulting in modifications to the multiple pathways that contribute to the morphological changes of the kidneys and ultimately to kidney damage. Nephropathy caused by diabetes is one of the most significant complications in terms of mortality and morbidity for patients with diabetes. The presence of proteinuria is a characteristic of diabetic nephropathy, and it is a type of chronic kidney disease caused by hyperglycemia. Diabetes patients are affected by it in approximately 20-40% of cases. In both types of diabetes, diabetic nephropathy risk is equal. Diabetes nephropathy market report provides information on market shares, new product developments, product pipeline analyses, impact of both domestic and localized market players, potential revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographical expansions, and technological innovations. Diabetic nephropathy is a very common indication for diabetic nephropathy, which is driving the market growth. Another factor driving the market growth is the presence of diabetic management centers across the world. Also impacting the growth of the diabetic nephropathy market are the aging population and high drug demand. The factors that hinder this market's growth include a lack of expertise or technically savvy professionals, on top of treatment costs, which significantly affect drug response. Diabetic nephropathy market also provides you with detailed market analysis of patient analysis, prognosis, and treatment. A multivariate statistical model for forecasting the market in the growth period is developed by analyzing the direct impact of epidemiology on market growth.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Diabetic Nephropathy Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Diabetic Nephropathy Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

  • Sun Pharmaceutical Industries Ltd
  • WOCKHARDT
  • Lupin
  • MerckCo.,Inc
  • Novartis AG
  • Zydus Cadila
  • Mylan N.V
  • Teva Pharmaceutical Industries Ltd
  • Amneal Pharmaceuticals LLC
  • Hetero
  • Macleods Pharmaceuticals Ltd
  • Sawai Pharmaceutical Co.Ltd
  • Aurobindo Pharma

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Drug Class

  • Diuretics
  • Antioxidant Inflammation Modulator
  • Angiotensin Receptor Blockers
  • Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)
  • Renin Inhibitors
  • Calcium Channel Blockers
  • Others

By Type

  • Type-1 Diabetes
  • Type-2 Diabetes

By Route of Administration

  • Oral
  • Parenteral
  • Others

By Distribution Channel

  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy

By End-Users

  • Hospitals
  • Homecare
  • Others

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Diabetic Nephropathy Market By Drug Class, By Type, By Route of Administration, By Distribution Channel, By End-Users and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Diabetic Nephropathy Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Diabetic Nephropathy Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Diabetic Nephropathy Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Diabetic Nephropathy Market, By Drug Class Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Diuretics
        2. Antioxidant Inflammation Modulator
        3. Angiotensin Receptor Blockers
        4. Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)
        5. Renin Inhibitors
        6. Calcium Channel Blockers
        7. Others

  • 8.   Diabetic Nephropathy Market, By Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Type-1 Diabetes
        2. Type-2 Diabetes

  • 9.   Diabetic Nephropathy Market, By Route of Administration Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Oral
        2. Parenteral
        3. Others

  • 10.   Diabetic Nephropathy Market, By Distribution Channels Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospital Pharmacy
        2. Online Pharmacy
        3. Retail Pharmacy

  • 11.   Diabetic Nephropathy Market, By End-Users Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospitals
        2. Homecare
        3. Others

  • 12.   North America Diabetic Nephropathy Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 13.   Latin America Diabetic Nephropathy Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 14.   Europe Diabetic Nephropathy Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 15.   Asia Pacific Diabetic Nephropathy Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 16.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Saudi Arabia
         2.2. UAE
         2.3. South Africa
         2.4. Egypt
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 17.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 18.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Sun Pharmaceutical Industries Ltd
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. WOCKHARDT
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Lupin
         3. 1. Company Overview
         3. 2. Product Portfolio
         3. 3. SWOT Analysis
         3. 4. Financial Overview
         3. 5. Strategic Overview
        4. MerckCo., Inc
         4.1. Company Overview
         4..2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Novartis AG
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Zydus Cadila
         6.1. Company Overview
         6. 2. Product Portfolio
         6. 3. SWOT Analysis
         6. 4. Financial Overview
         6. 5. Strategic Overview
        7. Mylan N.V
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Teva Pharmaceutical Industries Ltd
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
          9. Amneal Pharmaceuticals LLC
         9.1. Company Overview
         9.2. Product Portfolio
            9..3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Hetero
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
        11. Macleods Pharmaceuticals Ltd
         11.1. Company Overview
         11.2. Product Portfolio
         11.3. SWOT Analysis
         11.4. Financial Overview
         11.5. Strategic Overview
        12. Sawai Pharmaceutical Co.Ltd
         12.1. Company Overview
         12.2. Product Portfolio
         12.3. SWOT Analysis
         12.4. Financial Overview
         12.5. Strategic Overview
        13. Aurobindo Pharma
         13.1. Company Overview
         13.2. Product Portfolio
         13.3. SWOT Analysis
         13.4. Financial Overview
         13.5. Strategic Overview

  • 19.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by
                  administrations
        5. The overall economic slowdown of the developing and developed nations

  • 20.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients